Registered Clinical Research on Progressive Multiple Sclerosis (NCT07146087)

BioCells Medical is officially recognized as a sponsor and clinical site of an interventional trial registered on ClinicalTrials.gov (NCT07146087).This registration highlights our active contribution to the global scientific community and underlines our commitment to advancing regenerative neurology.

About the Study

• Population: Adults aged 18–65 with progressive MS (EDSS 3.0–6.5).

• Innovation: Intravenous administration of allogeneic MSC-derived exosomes, investigated for their potential to modulate neuroinflammation and promote neuroprotection.

• Design: 20 participants, four infusions over 48 weeks, with a comprehensive 24-month follow-up.

• Assessments: EDSS disability scale, MRI imaging, cognitive performance (SDMT), and biomarker analysis.
  

Why This Matters

Progressive multiple sclerosis remains one of the greatest unmet needs in neurology. Through this trial, BioCells Medical contributes to the global effort of developing innovative therapeutic approaches designed to stabilize, slow, or even halt disease progression — with rigorous scientific oversight and patient safety at the core.

Global Recognition

Listing on ClinicalTrials.gov, the world’s largest clinical research registry maintained by the U.S. National Library of Medicine, affirms BioCells Medical’s role as an internationally recognized contributor to regenerative medicine research.